Cargando…

Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer

BACKGROUND: The clinical impact of the biological heterogeneity within HER2-positive (HER2+) breast cancer is not fully understood. Here, we evaluated the molecular features and survival outcomes of the intrinsic subtypes within HER2+ breast cancer. METHODS: We interrogated The Cancer Genome Atlas (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prat, Aleix, Carey, Lisa A., Adamo, Barbara, Vidal, Maria, Tabernero, Josep, Cortés, Javier, Parker, Joel S., Perou, Charles M., Baselga, José
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4151853/ https://www.ncbi.nlm.nih.gov/pubmed/25139534 http://dx.doi.org/10.1093/jnci/dju152

Ejemplares similares

Intrinsic molecular subtypes of HER2+ breast cancer
por: Prat, Aleix, et al.
Publicado: (2017)

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
por: Prat, Aleix, et al.
Publicado: (2010)

Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy
por: Prat, Aleix, et al.
Publicado: (2015)

Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes
por: Prat, Aleix, et al.
Publicado: (2013)

Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status
por: Prat, Aleix, et al.
Publicado: (2014)

Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay
por: Desai, Neelam V., et al.
Publicado: (2018)

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2021)

Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report
por: Schettini, Francesco, et al.
Publicado: (2022)

A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes
por: Schettini, Francesco, et al.
Publicado: (2022)

Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis
por: Schettini, F., et al.
Publicado: (2023)

Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures
por: Fan, Cheng, et al.
Publicado: (2011)

Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse
por: Harrell, J. Chuck, et al.
Publicado: (2011)

Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
por: Prat, Aleix, et al.
Publicado: (2022)

Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer
por: Fernand ez-Martinez, Aranzazu, et al.
Publicado: (2017)

Deconstructing the molecular portraits of breast cancer
por: Prat, Aleix, et al.
Publicado: (2010)

Dissecting the biological heterogeneity of HER2-positive breast cancer
por: Schettini, Francesco, et al.
Publicado: (2021)

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
por: Pascual, Tomás, et al.
Publicado: (2019)

PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer
por: Prat, A., et al.
Publicado: (2012)

ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity
por: Prat, Aleix, et al.
Publicado: (2015)

Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity
por: Prat, Aleix, et al.
Publicado: (2013)

Subtype of SCLC Is an Intrinsic and Persistent Feature Through Systemic Treatment
por: Lo, Ying-Chun, et al.
Publicado: (2023)

Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
por: Prat, Aleix, et al.
Publicado: (2021)

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2019)

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
por: Brasó-Maristany, Fara, et al.
Publicado: (2020)

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial
por: Guarneri, Valentina, et al.
Publicado: (2022)

Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype
por: Couture, Heather D., et al.
Publicado: (2018)

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Schettini, Francesco, et al.
Publicado: (2021)

Zinc distribution within breast cancer tissue of different intrinsic subtypes
por: Rusch, Peter, et al.
Publicado: (2020)

Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Schettini, Francesco, et al.
Publicado: (2023)

HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
por: Bueno Muiño, Coralia, et al.
Publicado: (2022)

Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials
por: Fernandez-Martinez, Aranzazu, et al.
Publicado: (2023)

Characterizing intrinsic molecular features of the immune subtypes of salivary mucoepidermoid carcinoma
por: Kang, Hyundeok, et al.
Publicado: (2022)

An integrated genomics approach identifies drivers of proliferation in luminal subtype human breast cancer
por: Gatza, Michael L., et al.
Publicado: (2014)

The Significance of Serum HER2 Levels at Diagnosis on Intrinsic Subtype-Specific Outcome of Operable Breast Cancer Patients
por: Lee, Moo Hyun, et al.
Publicado: (2016)

Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy
por: Chic, Nuria, et al.
Publicado: (2021)

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
por: Vicario, Rocio, et al.
Publicado: (2015)

The relevance of the intrinsic subtype to the clinicopathological features and biomarkers in Japanese breast cancer patients
por: Tamaki, Masako, et al.
Publicado: (2013)

Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition
por: Roepman, Paul, et al.
Publicado: (2014)

EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast cancer
por: Soysal, S D, et al.
Publicado: (2013)

Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns
por: Bardowell, Sabrina A., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_27ntpqc7l7mjcimhd1ef0kkfh5